Autolus Therapeutics (AUTL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

AUTL · Stock Price

USD 1.61+0.26 (+19.26%)

Market Cap: $428.5M

Historical price data

Market Cap: $428.5MPipeline: 13 drugsPatents: 20Founded: 2014Employees: 201-500HQ: London, United Kingdom

Sector Ranking#46 in Cell & Gene Therapy #77 in Oncology (General)

Overview

Autolus Therapeutics is a UK-based biotech focused on developing advanced, programmed CAR T-cell therapies with the goal of delivering life-changing benefits to patients. Its most advanced asset, obecabtagene autoleucel (obe-cel), has demonstrated compelling clinical data in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and is progressing through late-stage development. The company's strategy hinges on its proprietary technology platform to create differentiated products, vertical integration for manufacturing control, and expansion into solid tumors and autoimmune diseases to build a diversified pipeline.

OncologyAutoimmune Diseases

Technology Platform

Proprietary Advanced Cell Programming platform that designs autologous CAR T-cells with integrated modules to enhance efficacy, safety, persistence, and tumor microenvironment engagement.

Pipeline

13

13 drugs in pipeline

Drug	Indication	Stage
AUTO CAR T cell therapy	Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy	Phase 2
Obecabtagene autoleucel	Lupus Nephritis	Phase 2
Obecabtagene autoleucel	Acute Lymphocytic Leukemia (ALL)	Phase 2
Obecabtagene Autoleucel	Acute Lymphoblastic Leukemia	Phase 2
AUTO3	Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 1/2

Funding History

4

Total raised:$360M

PIPE$100MBlackRockJul 15, 2020

IPO$150MUndisclosedJun 22, 2018

Series B$80MSynconaJul 15, 2017

Series A$30MSynconaJun 15, 2015

Opportunities

Approval and launch of obe-cel in r/r Adult B-ALL provides a near-term commercial catalyst.

The platform's application in larger NHL markets and the pioneering move into autoimmune diseases represent significant long-term expansion opportunities.

Vertical integration offers potential cost and supply chain advantages.

Risk Factors

High clinical and regulatory risk associated with lead asset obe-cel.

Pre-revenue status and dependence on capital markets create financial and dilution risk.

Intense competition in the CAR-T space from large pharma and biotech peers.

Unproven commercial execution for a first-time launcher.

Competitive Landscape

Competes directly with approved CD19 CAR-Ts (Tecartus, Kymriah) in B-ALL, where obe-cel aims to differentiate on safety. Faces broader competition in CAR-T from major players like Bristol Myers Squibb, Gilead, and Johnson & Johnson, as well as numerous biotechs developing next-generation technologies.